Insulet Corporation (PODD)
NASDAQHealth CareMedical DevicesSnapshot 2026-07-08
$157.46-2.53%
Close 2026-07-08 · 1-day change
Reading PODD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track PODD free→NASDAQHealth CareMedical DevicesSnapshot 2026-07-08
Reading PODD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track PODD free→QuarterlyIQ Insights · PODD
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Class II director — Jonathan J. Mazelsky: Appointment of Jonathan J. Mazelsky as a Class II director, effective July 1, 2026.
Regulation FD Disclosure On May 26, 2026, Insulet Corporation (the “Company”) issued a press release announcing a voluntary Medical Device Correction for specific lots of Omnipod® products due to a manufacturing issue identified through ongoing product monitoring. A copy of the press release is furnished herewith. This action is separate from the Company’s March 12, 2026 voluntary Medical Device Correction. The two actions involved different manufacturing processes, both of which were related…
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Regulation FD Disclosure On March 12, 2026, Insulet Corporation (the “Company”) issued a press release regarding a voluntary medical device correction. A copy of the press release is furnished herewith as Exhibit 99.1. While it is too early to ascertain the exact cost of the voluntary medical device correction, the Company currently expects to incur up to $40 million of costs associated with this event, all in 2026. These costs will be excluded from adjusted results. Accordingly, Insulet is n…
Chief Financial Officer — Ana M. Chadwick: The CFO departed the company and entered into a severance agreement.
Changes in Registrant’s Certifying Accountant On December 15, 2025, the Audit Committee of the Board of Directors of the Company notified GT, the Company’s then independent registered public accounting firm, that the Audit Committee selected PwC as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. GT was previously engaged to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2025. The…
Regulation FD Disclosure On February 13, 2026, the Board of Directors of Insulet Corporation (the “Company”) approved a $350 million increase in the previously authorized $125 million stock repurchase authorization and extended the authorization through December 31, 2027. With this additional authorization, the total authorization for the repurchase program allows for the purchase of up to $475 million in shares of the Company’s common stock. As of February 16, 2026, the Company has repurchas…
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Entry into a Material Definitive Agreement. On January 29, 2026, Insulet Corporation (the “ Company ”) and NXP USA, Inc. (“ NXP ”) entered into an Addendum effective January 1, 2026 (the “ 2026 Addendum”) to the Purchase Agreement, dated as of October 12, 2017, between the Company and NXP (the “ Original Agreement ”), as amended. Pursuant to the 2026 Addendum, the term of the Original Agreement, as amended, is extended, and certain terms and conditions related to pricing, product volume, prod…
of Form 8-K of Insulet Corporation dated December 15, 2025, and agree with the statements concerning our Firm contained therein. Very truly yours, GRANT THORNTON LLP 53 State Street, 16th Floor Boston, MA 02109 D +1 617 723 7900 F +1 617 723 6340
The filing pertains to the approval of amended and restated compensatory arrangements, not a management change.
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Director — Robbie Huffines: Appointment of Robbie Huffines as a Class II director and member of the Audit Committee.
Chief Financial Officer — Flavia H. Pease: Ms. Chadwick is departing and being succeeded by Ms. Pease, an external hire.
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Other Events. On June 9, 2025, the Company issued a notice of redemption (the “ Redemption Notice ”) for all of its outstanding 0.375% Convertible Senior Notes due 2026 (the “ Convertible Notes ” and the redemption thereof, the “ Redemption ”). Pursuant to the Redemption Notice, on August 20, 2025 (the “ Redemption Date ”), the Company will redeem any Convertible Notes that have not been converted, redeemed or repurchased prior to such date at a redemption price in cash equal to 100% of the p…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Entry into a Material Definitive Agreement. Credit Agreement Refinancing On June 6, 2025, Insulet Corporation (the “ Company ”) entered into the Eighth Amendment to Credit Agreement (the “ Amendment ”) with the lenders and other parties thereto and Morgan Stanley Senior Funding, Inc., as administrative agent (the “ Agent ”), amending that certain Credit Agreement, dated as of May 4, 2021 (as previously amended, supplemented or modified, the “ Credit Agreement ”, and as amended by the Amendmen…
Termination of Material Definitive Agreement The information set forth under
The filing is about the approval of a compensatory plan, not a management change.
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
President and Chief Executive Officer — James R. Hollingshead: James R. Hollingshead resigned as CEO and Director, succeeded by Ashley McEvoy.
Senior Vice President and Chief Technology Officer — Mark Field: Mr. Field left the Company and entered into a Consulting Services Agreement.
Regulation FD Disclosure. Note Repurchase Transactions On the Closing Date, the Company entered into separate and privately negotiated agreements with certain holders of the Company’s outstanding 0.375% Convertible Senior Notes due 2026 (the “Convertible Senior Notes”) pursuant to which the Company agreed to repurchase for cash consideration $419 million aggregate principal amount of the Convertible Senior Notes (such notes, the “Repurchased Notes”, and each such transaction, a “Note Repurcha…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth above in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.